Pancreatic ductal adenocarcinoma

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests a combination of two drugs, BXCL701 and pembrolizumab, in 22 people with advanced pancreatic cancer that has spread. The goal is to see if this treatment can stop the cancer from growing for at least 18 weeks. Participants must have already tried one prior treatm…

This early-stage trial tests a new drug called CA-4948 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the combination can shrink …

This Phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) and an immunotherapy drug (atezolizumab) to standard chemotherapy (mFOLFIRINOX) can keep pancreatic cancer from coming back after surgery. About 260 people whose tumors were completely remo…

This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…

This phase II trial tests whether adding an experimental drug called SHR-1701 to a standard chemotherapy regimen can improve outcomes for people with pancreatic cancer that is resectable or borderline resectable. Participants receive the combination before surgery, with the goal …

This phase III trial tests whether giving chemotherapy before and after surgery (perioperative) works better than giving it only after surgery (adjuvant) for people with pancreatic cancer that can be removed. The study involves 358 participants and uses a combination of four chem…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This Phase 3 trial is testing whether adding an experimental drug called quemliclustat to standard chemotherapy (nab-paclitaxel and gemcitabine) helps people with metastatic pancreatic cancer live longer. About 610 participants who have not yet received treatment for their advanc…

This study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior tr…

This study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…

This program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…

This early-stage trial tests whether adding three new drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are hard to remove. About 30 adults with borderline resectable or locally advanced pancreatic…

This Phase 2 trial is testing an experimental immunotherapy drug called QL1706 combined with standard chemotherapy (nab-paclitaxel and gemcitabine), with or without the targeted drug bevacizumab, as a first treatment for people with advanced pancreatic cancer that cannot be remov…

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This early-phase trial tests an experimental drug called BI 765049 in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest dose people can tolerate and to see if the drug helps the imm…

This early-stage trial is testing an investigational drug called GKL-006, given alongside standard chemotherapy, in people with advanced pancreatic cancer that cannot be removed by surgery. The study aims to see if the combination is safe and tolerable, and whether it shows any p…

This phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic dise…

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…

This phase II trial tests whether a combination of lenvatinib (a targeted drug) and pembrolizumab (an immunotherapy) can help keep advanced pancreatic cancer from progressing. The study includes 28 adults whose cancer has not spread further after initial treatment. Participants r…

This phase 2 trial is testing the safety and effectiveness of glipizide, a standard diabetes drug, for lowering blood sugar in people with pancreatic cancer. The study includes 29 participants with active pancreatic cancer and high blood sugar. Researchers will measure blood suga…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This early-phase trial is testing a vaccine that targets mutated KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with pancreatic or colorectal cancer that has been surgically removed. The goal is to see if the vaccine can safely boo…

This early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will …

This phase I trial tests pyrvinium pamoate, a drug originally used to treat pinworm infections, in people with pancreatic cancer that can be surgically removed. The goal is to find the safest dose and see if it can slow tumor growth. Researchers will monitor side effects and meas…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This study tests whether delivering a chemotherapy drug called floxuridine directly to the liver through a surgically placed pump can better control tumors that have spread from pancreatic cancer. Participants also receive standard chemotherapy. The goal is to see if this combina…

This phase 2 trial investigates whether adding sitagliptin, a diabetes medication, to standard chemotherapy (gemcitabine and nab-paclitaxel) can improve outcomes for people with advanced pancreatic cancer that has not been treated before. The study enrolls 30 adults with locally …

This trial tests whether adding an experimental drug called AMP945 to standard chemotherapy (nab-paclitaxel and gemcitabine) can improve tumor shrinkage in people with advanced pancreatic cancer that cannot be removed by surgery. The study has two parts: first, finding the best d…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…

This study tests a combination of two experimental drugs (AGEN1423 and botensilimab) with or without standard chemotherapy in people with advanced pancreatic cancer that has worsened after at least one prior treatment. The goal is to see if the combination can shrink tumors or sl…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This trial tests whether combining two drugs—SX-682 and nivolumab—can safely help people with metastatic pancreatic cancer that has not worsened after at least 16 weeks of first-line chemotherapy. The main goal is to find the highest tolerable dose of SX-682 when given with nivol…

This phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…

This study tests a new combination for people with pancreatic cancer that cannot be surgically removed or has spread. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab), alongside standard chemotherapy. The goal is to see i…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This early-stage trial is testing a personalized peptide vaccine for people with advanced pancreatic or colorectal cancer that has spread. The vaccine is made from each patient's own tumor cells and blood, aiming to train the immune system to attack the cancer. The study will che…

This trial investigates whether adding proglumide, a drug that blocks cholecystokinin receptors, to standard chemotherapy can improve treatment for metastatic pancreatic cancer. About 30 adults with advanced pancreatic cancer will receive either proglumide or a placebo alongside …

This study tests different combinations of immunotherapy drugs given before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if these treatments can help the immune system fight the cancer better and improve outcomes. About 76 participan…

This phase 3 trial tests a new drug called daraxonrasib (RMC-6236) against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug o…

This study tests whether adding the experimental drug navlimetostat to standard chemotherapy can help people with a specific type of advanced pancreatic cancer (one with an MTAP gene deletion) live longer or slow tumor growth. About 470 adults who have not had prior treatment for…

This phase 2 trial tests a low-dose combination of five chemotherapy drugs (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan) followed by two maintenance drugs (olaparib and pembrolizumab) in 38 people with untreated metastatic pancreatic cancer. The goal is to se…

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This early-phase trial is testing whether two drugs, HRS-4642 and nimotuzumab, can safely shrink tumors in people with recurrent or metastatic pancreatic ductal adenocarcinoma. About 20 patients will receive the combination to find the best dose and see how well it works. The goa…

This early-phase trial tests a new approach for people with pancreatic cancer that cannot be removed right away. Tiny nanoparticles called NBTXR3 are injected directly into the tumor and then activated by radiation therapy. The goal is to find a safe dose and see if this combinat…

This early-phase trial tests whether transferring healthy gut bacteria from donor stool can help control pancreatic cancer. Ten patients scheduled for tumor-removal surgery will receive the transplant to see if it is safe and affects the disease. The study is currently suspended.

This study tests whether a combination of three drugs (paricalcitol, hydroxychloroquine, and losartan) can safely modify the supportive tissue around pancreatic tumors before surgery. About 20 adults with resectable pancreatic cancer will take these drugs for at least 4 weeks bet…

This study tests whether giving chemotherapy both before and after surgery helps people with pancreatic cancer live longer compared to chemotherapy only after surgery. About 378 patients with resectable pancreatic cancer will be randomly assigned to one of two treatment schedules…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study was designed to see if giving two chemotherapy drugs (gemcitabine and capecitabine) after surgery could help people with pancreatic cancer stay cancer-free longer. It was for patients who had already received chemotherapy before surgery. However, the trial was withdraw…

This phase 2 trial tests a new drug called ZN-c3 combined with the chemotherapy gemcitabine in 12 people with advanced pancreatic cancer that has worsened after platinum-based treatment. The goal is to see if the combination is safe and can slow cancer growth. Participants take Z…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This study tests whether a special heat probe, inserted through an endoscope, can help people with inoperable pancreatic cancer live longer. About 108 participants will either receive the heat treatment plus standard care, or standard care alone. The trial is currently on hold, s…

This early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…

This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colon, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants w…

This early-phase trial tests whether adding two immune-boosting drugs (canakinumab and tislelizumab) to standard chemotherapy can safely shrink pancreatic tumors before surgery. Nine adults with resectable or borderline resectable pancreatic cancer will receive the combination. T…

This study tests a new drug called chiauranib combined with two standard chemotherapy drugs as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival. …

This early study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. Cancer cells need lots of cholesterol to grow, and this approach aims to starve them. The trial inc…

This study tests whether a 6-month program of exercise tracking and nutrition coaching is practical and acceptable for people with pancreatic cysts that raise cancer risk. Twenty-four participants will use a Fitbit and meet with counselors to increase activity and improve diet. T…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This study tests two experimental drugs, AK112 and cadonilimab, combined with standard chemotherapy as a first treatment for people with metastatic pancreatic cancer. About 110 participants will receive the combination to see if it is safe and helps shrink tumors. The goal is to …

This study tests whether taking pancreatic enzymes (Pertzye) with meals can help people with metastatic pancreatic cancer maintain their body weight during chemotherapy. The trial includes 17 participants who are starting a standard chemo regimen called FOLFIRINOX. Researchers wi…

This study tests whether combining two drugs, pembrolizumab and olaparib, can help people with a specific type of advanced pancreatic cancer keep their disease from growing. The trial includes 63 adults whose cancer has a genetic flaw called HRD or has responded well to platinum …

This study tests stereotactic body radiotherapy (SBRT), a precise, high-dose radiation given over 2 weeks, for people with high-risk localized pancreatic cancer. The goal is to see if it can stop the tumor from growing locally for at least 12 months. The trial includes 30 partici…

This study tests giving a single dose of chemotherapy directly into the liver artery before standard surgery and systemic chemo for localized pancreatic cancer. The goal is to see if this approach is safe and feasible in 20 patients. Researchers hope it may help prevent the cance…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase II trial tests whether switching from one chemotherapy regimen to another early on, before surgery, can help remove pancreatic cancer more completely. It includes patients with resectable, borderline resectable, or locally advanced unresectable pancreatic cancer. The s…

This phase II/III trial compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combo (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has BRCA1, BRCA2, or PALB2 gene mutations. T…

This early-phase trial is testing whether a personalized cancer vaccine, combined with an immunotherapy drug (atezolizumab) and chemotherapy, is safe for people with pancreatic cancer that has been surgically removed. The vaccine is made specifically for each patient based on the…

This phase IIb trial tests whether adding ATRA (a vitamin A derivative) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with locally advanced pancreatic cancer live longer without their cancer growing. About 170 participants will receive either the combo…

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …

This phase 2 trial tests whether adding a new antibody called HLX22 to standard treatment (trastuzumab plus chemotherapy) can shrink tumors and improve survival in people with HER2-positive pancreatic cancer that has spread. The study enrolls 45 adults who have not had prior trea…

This study tests whether adding an experimental drug called PEGPH20 to standard chemotherapy can help shrink advanced pancreatic cancer. PEGPH20 breaks down hyaluronan, a substance that builds up in pancreatic tumors and may help them grow. The trial includes 110 people with adva…

This phase 1 trial tests a combination of radiation therapy and the chemotherapy drug Abraxane (nab-paclitaxel) in people with pancreatic cancer that cannot be surgically removed. The goal is to find the safest and most effective doses to improve local tumor control and survival.…

This study tests a new method called sonoporation, which uses ultrasound and tiny gas bubbles to help chemotherapy drugs get into cancer cells more effectively. The trial includes 120 adults with advanced or hard-to-remove pancreatic cancer who are already receiving standard chem…

This study tests a new drug called mitazalimab combined with standard chemotherapy for people with metastatic pancreatic cancer that has spread. The goal is to see if the combination is safe and can shrink tumors. About 94 adults who have not had prior chemotherapy for this cance…

This early study tests whether adding the antibiotic ciprofloxacin to standard chemotherapy can help control metastatic pancreatic cancer. Ten patients who have not had prior treatment will receive the combination. The main goal is to see if the tumors shrink or stop growing.

This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…

This early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination fo…

This study tests whether adding two targeted drugs (avutometinib and defactinib) to standard chemotherapy can help people with metastatic pancreatic cancer that hasn't been treated yet. About 40 adults with this cancer will receive the combination. The goal is to find the safest …

This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aim…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This early-phase trial at Memorial Sloan Kettering is testing whether a special PET scan using an experimental tracer called 18F-FAC can show how much of the standard chemotherapy drug gemcitabine is taken up by pancreatic tumors. About 30 people with pancreatic ductal adenocarci…

This study is testing a mixed meal test to better diagnose a specific type of diabetes (type 3c) that occurs in people with pancreatic cancer or chronic pancreatitis. Researchers will enroll 775 adults aged 30 to 84 who have new-onset diabetes and one of these pancreatic conditio…

This early-phase study is testing whether a special PET scan using a drug called PYLARIFY can better detect cancer that has spread in people with pancreatic cancer, liver cancer, or breast cancer. About 36 adults will receive the scan, and doctors will compare the results to stan…

This study aimed to test a new two-step PET imaging method to better detect cancers that produce a substance called CA19-9, such as pancreatic, bladder, and gastrointestinal tumors. The plan was to give patients an antibody followed by a radioactive tracer to highlight cancer cel…

This trial is testing a new, noninvasive method called LINFU® that uses low-intensity ultrasound to stimulate the pancreas, helping to collect pancreatic juice for analysis. The goal is to see if this approach can detect early, asymptomatic pancreatic cancer and precancerous lesi…

This study tests an artificial intelligence model called PANDAPro that helps doctors spot pancreatic cancer on regular CT scans. Researchers will compare how well the AI finds cancers versus standard reading, and see if it catches tumors that were missed. The goal is to make scre…

This study is working on a new way to detect pancreatic cancer early using a simple urine and blood test. Researchers are collecting samples from 3500 people, both with and without pancreatic disease, to see if a panel of biomarkers can accurately identify cancer. The goal is to …

This study looks at whether measuring certain substances in bile and blood can more accurately diagnose cancer in people with bile duct blockages. Researchers will compare these new tests with standard methods in 500 adults undergoing a procedure called ERCP. The goal is to find …

This study tests whether a new type of MRI called 6D-MRI can predict how well pancreatic cancer patients respond to chemotherapy. Researchers will scan 36 patients before and during treatment to see if the MRI can spot signs of tumor activity and help guide surgery decisions. The…

Researchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…

This expanded access program gives seriously ill adults with advanced pancreatic cancer and cachexia (severe weight loss and muscle wasting) access to the experimental drug mifomelatide. Patients receive a daily injection for up to 13 weeks. The goal is to provide a potential tre…

This study looks at whether ketorolac, a common anti-inflammatory drug, is safe and can help stabilize or increase weight in people with advanced pancreatic cancer who are experiencing cachexia (severe weight loss). About 28 participants will take the drug four times daily for fi…

This study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …

This large study is testing whether a risk-scoring tool (called ENDPAC) can identify people with new-onset diabetes who are at higher risk for pancreatic cancer. About 8,800 participants aged 50-85 will have their medical records checked for age, weight changes, and blood sugar t…

This study looks at whether the spleen can be safely left in place during surgery for left-sided pancreatic cancer. Currently, the spleen is removed as a standard part of the operation to ensure any cancer in the surrounding fat is also taken out. The study will check how often c…

This study was designed to test new drug combinations for people with pancreatic cancer that hasn't spread. It planned to compare new treatments against standard chemotherapy in three groups based on how far the cancer had grown. However, the study was withdrawn before enrolling …

This study explores whether ultrasound images analyzed by a special computer program can accurately measure the size of liver tumors in people with pancreatic or gastrointestinal cancer that has spread to the liver. Participants will have both a routine contrast-enhanced CT scan …

This study looks at people with pancreatic cancer to find genetic factors that may increase risk. Researchers will collect medical and family history and test for gene mutations. The goal is to build a tool that can better identify who is at risk for this disease. 271 participant…

This study looks at whether a biomarker called GATA6 can help predict how well patients with resectable pancreatic cancer respond to chemotherapy before and after surgery. About 84 participants will provide tumor samples to measure GATA6 levels, then receive a standard chemo regi…

This registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.

This study enrolls 200 people with pancreatic cancer across Ontario. Researchers collect tumor tissue, blood, and stool samples to perform genetic sequencing and grow mini-tumors in the lab. The goal is to see if this detailed analysis helps more patients receive a treatment matc…

This study aims to create computer models that predict how long patients with advanced pancreatic cancer might live and how well they respond to chemotherapy. Researchers will use medical images, tissue samples, and genetic data from 100 patients. The goal is to help doctors make…

This study is collecting blood samples from 102 patients with non-small cell lung cancer, colorectal cancer, or pancreatic cancer who are receiving standard treatments. Researchers will analyze the blood for cancer DNA (ctDNA) to see how it changes over time and whether it relate…

This study creates a registry for people with BRCA or PALB2 gene mutations who have pancreatic cancer, along with their close relatives. Researchers will collect medical information, blood samples, and tumor tissue to better understand why pancreatic cancer develops in this group…

This study aims to develop a way to predict which patients with advanced pancreatic cancer will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 100 participants before and during treatment. By analyzing these samples, they hope to cr…

This study follows 500 adults with pancreatic cancer who had surgery intended to remove all visible cancer. Researchers want to learn how often the cancer returns within the first year, where it shows up (like the liver or lungs), and how it is detected. Participants receive stan…